Angiographic regression of cardiac allograft vasculopathy after introducing sirolimus immunosuppression

Journal of Heart and Lung Transplantation

Volumn 22, Issue 11, 2003, Pages 1276-1279

  Ruygrok, Peter N ^a   Webber, Bruce ^a   Faddy, Stephen ^b   Muller, David W ^b   Keogh, Anne ^b  

^a GREEN LANE HOSPITAL   (New Zealand)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; AZATHIOPRINE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; OKT 3; PRAVASTATIN; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS;

ADULT; ANAMNESIS; ANGIOCARDIOGRAPHY; ARTICLE; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; DRUG DOSE REDUCTION; DRUG INDICATION; GRAFT FAILURE; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0142247235     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(02)01239-1     Document Type: Article

References (28)

1. Bieber C.P., Hunt S.A., Schwinn D.A., et al. Complications in long-term survivors of cardiac transplantation. Transplant Proc. 13:1981;207-211.
2. Gao S.Z., Hunt S.A., Schroeder J.S., Alderman E.L., Hill I.R., Stinson E.B. Early development of accelerated graft coronary disease risk factors and course. J Am Coll Cardiol. 28:1996;673-679.
3. Gallo P., Agozzino L., Angelini A., et al. Causes of late failure after heart transplantation a ten-year survey. J Heart Lung Transplant. 16:1997;1113-1121.
4. Costanzo M.R., Naftel D.C., Pritzker M.R., et al. Heart transplant coronary artery disease detected by coronary angiography a multi-institutional study of preoperative donor and recipient risk factors. J Heart Lung Transplant. 17:1998;744-753.
5. Julius B.K., Attenhofer Jost J.B.K., Sutsch G., et al. Incidence, progression and functional significance of cardiac allograft vasculopathy after cardiac transplantation. Transplantation. 69:2000;847-853.
6. Rickenbacher P.R., Pinto F.J., Chenzbraun A., et al. Incidence and severity of transplant coronary artery disease early and up to 15 years after transplantation as detected by intravascular ultrasound. J Am Coll Cardiol. 25:1995;171-177.
7. Vezina C., Kudelski A., Senegal S.N. Sirolimus (AY-22, 989), a new antifungal antibiotic Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot. 28:1975;721-726.
8. Marx S.O., Jayaraman T., Go L.O., Marks A.R. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res. 76:1995;412-417.
9. Poon M., Marx S.O., Gallo R., et al. Rapamycin inhibits vascular smooth cell migration. J Clin Invest. 98:1996;2277-2283.
10. Marx S.O., Marks A.R. The development of rapamycin and its application to stent restenosis. Circulation. 104:2001;852-859.
11. Dumont F.J., Staruch M.J., Kooprak S.L., et al. Distinct mechanisms of suppression of murine T-cell activation by the related macrolides FK-506 and rapamycin. J Immunol. 144:1990;251-258.
12. Morice W.G., Brunn G.J., Wiederrecht G., et al. Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes. J Biol Chem. 268:1993;3734-3738.
13. Cao W., Mohasci P., Shorthouse R., Pratt R., Morris R.E. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation. 59:1995;390-395.
14. Pham S.M., Shears L.L., Kawaharada N., et al. High local production of nitric oxide as a possible mechanism by which rapamycin prevents transplant arteriosclerosis. Transplant Proc. 30:1998;953-954.
15. Hayry P., Aavik E., Savolainen H. Mechanisms of chronic rejection. Transplant Proc. 31:1999;5S-8S.
16. Schmid C., Heemann U., Tilney N.L. Factors contributing to the development of chronic rejection in heterotopic rat heart transplantation. Transplantation. 64:1997;222-228.
17. Geerling RA, Ansari AA, LaFond-Walker, et al. Accelerated arteriosclerosis in aortic grafts: a role for activated complement and IgM antibody in early lesion development. Transplant Proc 1998;30:1017-9.
18. Billingham M.E. Histopathology of graft coronary disease. J Heart Lung Transplant. 11:1992;S38-44.
19. Schmid C., Heemann U., Azuma H., Tilney N.L. Comparison of rapamycin RS 61443, cyclosporine, and low dose heparin as treatment for transplant vasculopathy in a rat model of chronic allograft rejection. Transplant Proc. 27:1995;438-439.
20. Schmid C., Heemann U., Azuma H., Tilney N.L. Rapamycin inhibits transplant vasculopathy in long-surviving rat heart allografts. Transplantation. 60:1995;729-733.
21. Meiser B.M., Billingham M.E., Morris R.E. Effects of cyclosporine, FK506, and rapamycin on graft vessel disease. Lancet. 338:1991;1297-1298.
22. Wasowska B., Hancock W.W., Onodera K., et al. Rapamycin and cyclosporine A treatment a novel regimen to prevent chronic allograft rejection in sensitized hosts. Transplant Proc. 29:1997;333.
23. Goggins W.C., Fisher R.A., Cohen D.S., et al. Effect of single-dose rapamycin-based immunosuppression on the development of cardiac allograft vasculopathy. J Heart Lung Transplant. 15:1996;790-795.
24. Geerling RA, De Bruin RWF, Scheringa M, et al. Suppression of acute rejection prevents graft arteriosclerosis after allogeneic aorta transplantation in the rat. Transplantation 1994;58:1258-63.
25. Poston R.S., Billingham M., Hoyt E.G., et al. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation. 100:1999;67-74.
26. Eisen H., Dorent R., Mancini H., et al. Safety and efficacy of everolimus as part of a triple immunosuppressive regimen in de novo cardiac transplant recipients; six month analysis (abstract). J Heart Lung Transplant. 21:2002;55.
27. Keogh A, Muller D, Richardson M, Ruygrok PN, O'Driscoll G, Galbraith A. Rapamycin: results of a randomised trial following heart transplantation. Presented at the annual scientific meeting of the International Society for Heart and Lung Transplantation, Washington, April 2002.
28. Tuzcu E.M., Schoenhagen P., Starling R.C., et al. Impact of everolimus on allograft vasculopathy; the SDZ RAD/Heart Intravascular Ultrasound Study (abstract). J Heart Lung Transplant. 21:2002;68.